# Bone Health in Gynecologic Cancers-does FOSAVANCE Help?

> **NCT00593580** · PHASE2 · COMPLETED · sponsor: **British Columbia Cancer Agency** · enrollment: 60 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** placebo
- **DRUG:** alendronate/cholecalciferol

## Key facts

- **NCT ID:** NCT00593580
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2011-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00593580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00593580, "Bone Health in Gynecologic Cancers-does FOSAVANCE Help?". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00593580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*